Orange Biomed’s at-home A1C testing device could be a potential disrupter in prediabetes and diabetes care. The Orange Biomed device, called OBM Rapid A1C, also does not use protein reagents, eliminating the need for frequent calibrations, Ko said. And the new technology is not affected by variance in hemoglobin proteins…
Orange Biomed is making a portable device to produce more accurate A1C readings for Black diabetics. Current tests show higher numbers due to red blood cell lifespan differences. This device helps to improve diabetes care for better results. It is in clinical trials and pending FDA clearance.
Diabetes is a typical chronic disease that affects more than 500 million patients worldwide. In the early stages, there are no clear symptoms, but if left untreated, complications and treatment burdens increase exponentially. Therefore, diabetes management goes beyond simply measuring blood sugar levels every day…
The future of healthcare is on display at CES 2025, with five innovative digital health startups backed by Digital Healthcare Partners (DHP) showcasing groundbreaking technologies poised to revolutionize wellness and patient care.
Orange Biomed is developing a small medical device called ‘OBM rapid A1c’ that can measure glycated hemoglobin levels, which are essential for diabetes management, at home with a single blood sample based on microfluidic technology. In particular, Orange Biomed plans to target the U.S. market, where medical accessibility is low…
Five portfolio startups invested by Digital Healthcare Partners (DHP) will participate in the world’s largest information technology (IT) and home appliance exhibition, ‘CES 2025’… They plan to network with local experts and industry insiders at CES and explore opportunities to enter global markets.
“Enhancing Healthcare Equity with Cutting-Edge Medical Devices” Orange Biomed will showcase its portable HbA1c monitor, OBM rapid A1c… The OBM rapid A1c is a groundbreaking device designed to simplify diabetes management by enabling accurate and convenient hemoglobin A1c testing at home.
Orange Biomed announced that it will be participating in Eureka Park at CES 2025, held in Las Vegas, Nevada, USA from January 7 to 10, and will be introducing the portable glycated hemoglobin measuring device, ‘OBM rapid A1c’.
“We will increase medical equity with cutting-edge medical devices!” Orange Biomed announced that it will participate in the ‘K-Startup Pavilion’ at CES 2025…
Bio startup Orange Biomed is entering the global market with its personal glycated hemoglobin (HbA1c) measuring medical device. Based on its miniaturization technology…
At COMEUP, Orange Biomed, which possesses technology to monitor diabetes with a single drop of blood, is a Rocket League company that received Series A investment…
Diabetes is a silent disease. For management, glycated hemoglobin must be measured. With Orange Biomed, the periodic management of glycated hemoglobin is possible…
Recognition of clinical research results for innovative microfluidic technology-based portable glycated hemoglobin meter,
participation in CES Eureka Park in 2025 to fully advance into the US market.
Yeaseul Park, CEO of Orange Biomed, is a Forbes 30 Under 30 honoree. What is the efficacy of this new device? Interview by Scott Douglas Jacobsen. Park discusses the development of their innovative A1C diabetes management device…
“Ultimately, this leads to better health outcomes by making diabetes management more accessible and proactive,” said Yeaseul Park, Co-Founder and Co-President Orange Biomed, USA.
Attendees get an early preview of Orange Biomed’s revolutionary A1C testing method, recognized as a groundbreaking solution with anticipated release in 2025…
